

## ABSTRACT&amp;REFERENCES

DOI: 10.15587/2519-4798.2018.127082

**EFFECTIVENESS OF THE DOSED INDIVIDUAL ISOMETRIC PHYSICAL EXERCISE IN PATIENTS WITH KNEE OSTEOARTHRITIS**

p. 4-9

**Valerii Novoseletskyi**, Assistant, Department of Internal Medicine No. 1, National Pirogov Memorial Medical University, Pyrohova str., 56, Vinnytsya, Ukraine, 21018

E-mail: valerii.novoseletskyi@gmail.com

ORCID: <http://orcid.org/0000-0002-7713-6868>

**Aim of the work:** to evaluate the effectiveness of dosed individualized isometric physical activity in patients with OA of knee joints.

**Materials and methods.** Measurement of maximum isometric force of the flexor / extensor leg muscles was done in 71 patients with OA of knee joints and 32 practically healthy women. Muscle strength, quality of life, as well as the dynamics of blood serum leptin content in response to the course of physical activity in patients with OA was evaluated.

**Results.** A significant decrease ( $p < 0.05$ ) in flexor / extensor muscle strength in the OA patients was found in relation to the control group subjects. The proposed program of physical rehabilitation was effective in increasing muscle strength of the lower limbs, reducing the intensity of the pain syndrome and improving the quality of life. There were no significant differences in the levels of leptin in response to physical activity in patients with OA, using the WinBUGS method.

**Conclusions.** The proposed dosed individualized isometric physical activity in patients with OA increases muscle strength, reduces the severity of the pain syndrome, increases the functional capacity of patients, which is the reason for its inclusion in the complex of treatment in this category of patients

**Keywords:** Osteoarthritis, isometric physical activity, KOOS, WOMAC, HAQ, Lequesne index, leptin

**References**

1. Fernandes, L., Hagen, K. B., Bijlsma, J. W. J., Andreassen, O., Christensen, P., Conaghan, P. G. et. al. (2013). EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. *Annals of the Rheumatic Diseases*, 72 (7), 1125–1135. doi: 10.1136/annrheumdis-2013-204801
2. McAlindon, T. E., Bannuru, R. R., Sullivan, M. C., Arden, N. K., Berenbaum, F., Bierma-Zeinstra, S. M. et. al. (2014). OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis and Cartilage*, 22 (3), 363–388. doi: 10.1016/j.joca.2014.01.003
3. Fransen, M., McConnell, S. (2008). Exercise for osteoarthritis of the knee. *Cochrane Database of Systematic Reviews*, 8. doi: 10.1002/14651858.cd004376.pub2
4. Sharma, S. K., Yadav, S. L., Singh, U., Wadhwa, S. (2017). Muscle Activation Profiles and Co-Activation of Quadriceps and Hamstring Muscles around Knee Joint in Indian Primary Osteoarthritis Knee Patients. *Journal Of Clinical And Diagnostic Research*, 11 (5), 9–14. doi: 10.7860/jcdr/2017/26975.9870
5. Koehler, K., Hoerner, N. R., Gibbs, J. C., Zinner, C., Braun, H., De Souza, M. J., Schaenzer, W. (2016). Low energy availability in exercising men is associated with reduced leptin and insulin but not with changes in other metabolic hormones. *Journal of Sports Sciences*, 34 (20), 1921–1929. doi: 10.1080/02640414.2016.1142109
6. Zaccaria, M., Ermolao, A., Roi, G., Englaro, P., Tegon, G., Varnier, M. (2002). Leptin reduction after endurance races differing in duration and energy expenditure. *European Journal of Applied Physiology*, 87 (2), 108–111. doi: 10.1007/s00421-002-0606-4
7. Braun, W. A., Hawthorne, W. E., Markofski, M. M. (2005). Acute EPOC response in women to circuit training and treadmill exercise of matched oxygen consumption. *European Journal of Applied Physiology*, 94 (5-6), 500–504. doi: 10.1007/s00421-005-1383-7
8. Sari, R., Balci, M. K., Balci, N., Karayalcin, U. (2007). Acute Effect of Exercise on Plasma Leptin Level and Insulin Resistance in Obese Women with Stable Caloric Intake. *Endocrine Research*, 32 (1-2), 9–17. doi: 10.1080/07435800701670070
9. Knuttgen, H. G. (2007). Strength Training and Aerobic Exercise: Comparison and Contrast. *The Journal of Strength and Conditioning Research*, 21 (3), 973–978. doi: 10.1519/r-505011.1
10. McCarthy, C., Mills, P., Pullen, R., Richardson, G., Hawkins, N., Roberts, C. et. al. (2004). Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis. *Health Technology Assessment*, 8 (46). doi: 10.3310/hta8460
11. Elbadawy, M. A. (2017). Effectiveness of Periosteal Stimulation Therapy and Home Exercise Program in the Rehabilitation of Patients With Advanced Knee Osteoarthritis. *The Clinical Journal of Pain*, 33 (3), 254–263. doi: 10.1097/ajp.0000000000000404
12. Akyol, Y., Durmus, D., Alayli, G., Tander, B., Bek, Y., Canturk, F. et. al. (2010). Does short-wave diathermy increase the effectiveness of isokinetic exercise on pain, function, knee muscle strength, quality of life, and depression in the patients with knee osteoarthritis? A randomized controlled clinical study. *European Journal of Physical and Rehabilitation Medicine*, 46 (3), 325–336.

13. Deyle, G. D., Henderson, N. E., Matekel, R. L., Ryder, M. G., Garber, M. B., Allison, S. C. (2000). Effectiveness of Manual Physical Therapy and Exercise in Osteoarthritis of the Knee. *Annals of Internal Medicine*, 132 (3), 173–181. doi: 10.7326/0003-4819-132-3-200002010-00002
14. Chang, W.-J., Bennell, K. L., Hodges, P. W., Hinman, R. S., Liston, M. B., Schabrun, S. M. (2015). Combined exercise and transcranial direct current stimulation intervention for knee osteoarthritis: protocol for a pilot randomised controlled trial: Table 1. *BMJ Open*, 5 (8), e008482. doi: 10.1136/bmjopen-2015-008482
15. McCarthy, C. J., Mills, P. M., Pullen, R., Roberts, C., Silman, A., Oldham, J. A. (2004). Supplementing a home exercise programme with a class-based exercise programme is more effective than home exercise alone in the treatment of knee osteoarthritis. *Rheumatology*, 43 (7), 880–886. doi: 10.1093/rheumatology/keh188
16. Lim, B., Hinman, R. S., Wrigley, T. V., Sharma, L., Bennell, K. L. (2008). Does knee malalignment mediate the effects of quadriceps strengthening on knee adduction moment, pain, and function in medial knee osteoarthritis? A randomized controlled trial. *Arthritis & Rheumatism*, 59 (7), 943–951. doi: 10.1002/art.23823
17. Regnaud, J., Lefevre-Colau, M., Trinquart, L., Nguyen, C., Boutron, I., Brosseau, L., Ravaud, P. (2015). High-intensity versus low-intensity physical activity or exercise in people with hip or knee osteoarthritis. *Cochrane Database of Systematic Reviews*, 10. doi: 10.1002/14651858.cd010203.pub2
18. Arden, N. K., Leyland, K. M. (2013). Osteoarthritis year 2013 in review: clinical. *Osteoarthritis and Cartilage*, 21 (10), 1409–1413. doi: 10.1016/j.joca.2013.06.021
19. Van der Esch, M., Knoop, J., Hunter, D. J., Klein, J.-P., van der Leeden, M., Knol, D. L. et. al. (2013). The association between reduced knee joint proprioception and medial meniscal abnormalities using MRI in knee osteoarthritis: results from the Amsterdam osteoarthritis cohort. *Osteoarthritis and Cartilage*, 21 (5), 676–681. doi: 10.1016/j.joca.2013.02.002
20. Febbraio, M. A., Pedersen, B. K. (2002). Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. *The FASEB Journal*, 16 (11), 1335–1347. doi: 10.1096/fj.01-0876rev
21. Knoop, J., Dekker, J., van der Leeden, M., van der Esch, M., Thorstensson, C. A., Gerritsen, M. et. al. (2013). Knee joint stabilization therapy in patients with osteoarthritis of the knee: a randomized, controlled trial. *Osteoarthritis and Cartilage*, 21 (8), 1025–1034. doi: 10.1016/j.joca.2013.05.012
22. Runhaar, J., Luijsterburg, P., Dekker, J., Bierma-Zeinstra, S. M. A. (2015). Identifying potential working mechanisms behind the positive effects of exercise therapy on pain and function in osteoarthritis; a systematic review. *Osteoarthritis and Cartilage*, 23 (7), 1071–1082. doi: 10.1016/j.joca.2014.12.027
23. Stanislavchuk, M. A., Novoseletskyi, V. O. (2013). Pat. No. 81950 UA. Vymiruvach syly m'iazivnyzhnikh kintsivok. MPK: A61B 5/22. No. u 201302319; declared: 25.02.2013; published: 10.07.2013, Bul. No. 13.
24. Fransen, M., McConnell, S., Harmer, A. R., Van der Esch, M., Simic, M., Bennell, K. L. (2015). Exercise for osteoarthritis of the knee. *Cochrane Database of Systematic Reviews*, 1. doi: 10.1002/14651858.cd004376.pub3
25. Nindl, B. C., Kraemer, W. J., Arciero, P. J., Samatallee, N., Leone, C. D., Mzayo, M. F., Hafeman, D. L. (2002). Leptin concentrations experience a delayed reduction after resistance exercise in men. *Medicine & Science in Sports & Exercise*, 34 (4), 608–613. doi: 10.1249/00005768-200204000-00008
26. Ara, I., Perez-Gomez, J., Vicente-Rodriguez, G., Chavarren, J., Dorado, C., Calbet, J. A. L. (2006). Serum free testosterone, leptin and soluble leptin receptor changes in a 6-week strength-training programme. *British Journal of Nutrition*, 96 (6), 1053–1059. doi: 10.1017/bjn20061956
27. Ishigaki, T., Koyama, K., Tsujita, J., Tanaka, N., Hori, S., Oku, Y. (2005). Plasma Leptin Levels of Elite Endurance Runners after Heavy Endurance Training. *Journal of Physiological Anthropology and Applied Human Science*, 24 (6), 573–578. doi: 10.2114/jpa.24.573
- 
- DOI: 10.15587/2519-4798.2018.127557**
- STUDY THE QUALITY OF LIFE AND ANXIETY IN PATIENTS WITH MYASTHENIA (CLINICAL-PARACHLINAL COMPARISON)**
- p. 10-13**
- Oleksandr Kalbus**, PhD, Assistant, Department of Neurology and Ophthalmology, SE “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Volodymyra Vernadskoho str., 9, Dnipro, Ukraine, 49044  
E-mail: kalbus.dp@gmail.com  
ORCID: <http://orcid.org/0000-0003-0796-4825>
- Aim of the research:** To investigate the level of anxiety in adult patients with myasthenia.
- Materials and methods.** An in-depth clinical-neurological, immunological (detection of antibodies to acetylcholine and/or muscle-specific tyrosine kinase receptors) examination, testing according to MGQoL-15 scale, and Spielberg-Khanin anxiety scale of 96 patients (56 women and 40 men) with myasthenia (71 – with generalized, 25 – with an ophthalmologic form, respectively) were done.
- Results.** Antibodies to acetylcholine receptors were detected in 57 (80.3 %) of 71 patients with generalized form and in 13 (52 %) of 25 patients with ophthalmic myasthenia, antibodies to muscle-specific tyrosine kinase in

6 (8.5 %) of 71 patients with generalized form. In the case of an ophthalmic form, these antibodies were not detected. In 8 (11.3 %) out of 71 patients with generalized myasthenia and in 12 (48.0 %) out of 25 patients with ophthalmic form of myasthenia antibodies to acetylcholine receptors and muscle-specific tyrosine kinase were not detected.

When the MGQoL-15 scale was used, the average quality of life was  $10.34 \pm 9.4$  points (ranging from 0 to 31).

In assessing of situational anxiety, a moderate level of anxiety was detected in 44 patients, high – in 24 patients, while the low level of anxiety had 28 people. Patients with an ophthalmic form of myasthenia (class I by MGFA) are significantly more likely to have a low level of anxiety ( $p < 0.05$ ). The moderate level of situational anxiety was significantly more frequently recorded in patients with myasthenia class III by MGFA (moderate form), and high level – in patients with myasthenia class IV by MGFA (expressed form). In patients with a low level of situational anxiety, the average duration of the disease was significantly lower ( $p < 0.05$ ).

When comparing the quality of life in patients with myasthenia with the MGQoL-15 scale and the level of situational anxiety with the Spielberg-Khanin scale, there was a significant negative impact of increased anxiety on quality of life ( $r = -0.24$ ,  $p = 0.01$ )

**Conclusions.** The quality of life of patients with myasthenia and the level of anxiety disorders do not depend on the immunological subtype of the disease. The quality of life of patients with myasthenia is largely dependent on the degree of clinical manifestations of the disease. The increased level of situational anxiety reliably reduces the quality of life

**Keywords:** myasthenia, anxiety, antibodies to acetylcholine receptors, quality of life

## References

1. Kulikova, S. L. (2014). Antitela k atsetilholinovim retseptoram v diagnostike razlichnyih form miastenii. *Nevrologiya i neyrohirurgiya Vostochnaya Evropa*, 1 (21), 73–82.
2. Skeie, G. O., Apostolski, S., Evoli, A., Gilhus, N. E., Illa, I., Harms, L. et. al. (2010). Guidelines for treatment of autoimmune neuromuscular transmission disorders. *European Journal of Neurology*, 17 (7), 893–902. doi: 10.1111/j.1468-1331.2010.03019.x
3. Shkolnik, V. M., Kalbus, A. I., Baranenko, A. N., Pogorelov, A. V. (2014). Miastenija: sovremennye podhody k diagnostike i lecheniyu. *Ukrainskyi nevrolohični žurnal*, 2, 12–17.
4. Shkolnik, V. M., Kalbus, A. I., Shulga, O. D. (2010). Miastenija: chto nam izvestno segodnya? *Zdorovia Ukrainy (nevrolohiia, psykhiaetriia, psykhoterapiya)*, 3 (14), 10–11.
5. Shulga, O. D., Kalbus, A. I., Shulga, L. A. (2010). Miastenija. *Neyron Revyu*, 2, 13–20.
6. Kulaksizoglu, I. B. (2007). Mood and Anxiety Disorders in Patients with Myasthenia Gravis. *CNS Drugs*, 21 (6), 473–481. doi: 10.2165/00023210-200721060-00004
7. Aysal, F., Karamustafalıoğlu, O., Özçelik, B. et. al. (2013). The relationship of symptoms of anxiety and depression with disease severity and treatment modality in myasthenia gravis: a cross-sectional study. *Archives of Neuropsychiatry*, 50 (4), 295–300. doi: 10.4274/npa.y5611
8. Uyaroglu F. G., Bilgin S., Keleş E. H., Zorlu Y. (2016). Anxiety And Depression Symptoms In Patients With Generalized Myasthenia Gravis. *The Journal of Tpecik Education and Research Hospital*, 26 (2), 97–103. doi: 10.5222/terh.2016.097
9. Suzuki, Y., Utsugisawa, K., Suzuki, S., Nagane, Y., Masuda, M., Kabasawa, C. et. al. (2011). Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. *BMJ Open*, 1 (2), e000313–e000313. doi: 10.1136/bmjopen-2011-000313
10. Blum, S., Lee, D., Gillis, D., McEniery, D. F., Reddel, S., McCombe, P. (2015). Clinical features and impact of myasthenia gravis disease in Australian patients. *Journal of Clinical Neuroscience*, 22 (7), 1164–1169. doi: 10.1016/j.jocn.2015.01.022
11. Kulkantrakorn, K., Sawanyawisuth, K., Tiamkao, S. (2010). Factors correlating quality of life in patients with myasthenia gravis. *Neurological Sciences*, 31 (5), 571–573. doi: 10.1007/s10072-010-0285-6
12. Padua, L., Evoli, A., Aprile, I., Caliandro, P., Mazza, S., Padua, R., Tonali, P. (2001). Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. *Neurological Sciences*, 22 (5), 363–369. doi: 10.1007/s100720100066
13. Oliveira, E. F., Nacif, S. R., Urbano, J. J., Silva, A. S., Oliveira, C. S., Perez, E. A. et. al. (2017). Sleep, lung function, and quality of life in patients with myasthenia gravis: A cross-sectional study. *Neuromuscular Disorders*, 27 (2), 120–127. doi: 10.1016/j.nmd.2016.11.015
14. Yang, Y., Zhang, M., Guo, J., Ma, S., Fan, L., Wang, X. et. al. (2015). Quality of life in 188 patients with myasthenia gravis in China. *International Journal of Neuroscience*, 126 (5), 455–462. doi: 10.3109/00207454.2015.1038712

DOI: 10.15587/2519-4798.2018.127424

## CYTOCHEMICAL EXAMINATION OF BLOOD CELLS OF CHILDREN WITH CHRONIC TONSILLITIS AND TYPE 1 DIABETES MELLITUS

p.13-17

Iurii Gavrylenko, PhD, Assistant, Department of Pediatric Otorhynolaryngology, Audiology, Phoniatry, Shupyk

National Medical Academy of Post-Graduate Education,  
Dorohozhytska str., 9, Kyiv, Ukraine, 04112

E-mail: yesyur@ukr.net, yesyur69@gmail.com

ORCID: <http://orcid.org/0000-0003-3828-3248>

**Andrey Laiko**, MD, Professor, Department of Pediatric  
Otorhinolaryngology, Audiology, Phoniatriy, Shupyk Na-  
tional Medical Academy of Post-Graduate Education, Do-  
rohozhyska str., 9, Kyiv, Ukraine, 04112

**Anton Karas**, PhD, Head of Laboratory, Laboratory of  
Biophysics, State Enterprise «O. S. Kolomiychenko In-  
stitute of Otolaryngology National Academy of Medical  
Sciences of Ukraine», Zoolohichna str., 3, Kyiv, Ukraine,  
03057

E-mail: karasaf@bigmir.net

**Halyna Karas**, PhD, Senior Researcher, Laboratory of  
Biophysics, State Enterprise «O. S. Kolomiychenko In-  
stitute of Otolaryngology National Academy of Medical  
Sciences of Ukraine», Zoolohichna str., 3, Kyiv, Ukraine,  
03057

E-mail: gkaras@ukr.net

**Aim of the work:** to study the state of the enzyme activity  
of the energy exchange of succinate dehydrogenase (SDH)  
and hydrolytic enzyme acid phosphatase (AF) in neutro-  
phils and lymphocytes on the basis of their cytochemical  
study in blood cells of children with CT in combination  
with DM 1.

**Materials and methods:** the blood of 41 children aged  
from 6 to 12 years was examined. All patients were divid-  
ed into 2 clinical groups: the first (main) group included  
30 children, who were diagnosed with CT in combination  
with DM 1, and the second (control group of comparison)  
- 11 children with CT without DM 1. Blood smears were  
examined under a light microscope and an oil immersion.  
The results were evaluated by a semi-quantitative method,  
with the calculation of the average cytochemical coeffi-  
cient (ACC)

**Results:** a significant decrease in SDH was observed in  
the group of patients with CT in combination with DM 1,  
and ACC was respectively, for neutrophils,  $0.85 \pm 0.22$  and  
 $1.27 \pm 0.31$  for lymphocytes, as compared with patients  
with only CT for neutrophils  $0.37 \pm 0.18$  ( $p < 0.05$ ), and  
 $0.53 \pm 0.12$  ( $p < 0.05$ ) for lymphocytes. The combination of  
DM 1 and CT reduces the activity of the lysosomal enzyme  
acid phosphatase. At the same time, the ACC of AF with  
a combined pathology is  $0.286 \pm 0.07$  for neutrophils and  
 $0.165 \pm 0.055$  for lymphocytes, and  $0.361 \pm 0.057$  ( $p < 0.05$ )  
and  $0.213 \pm 0.038$  ( $p < 0.05$ ), respectively, for comparison  
with CT.

**Conclusions:** the revealed changes in the cytochemical  
characteristics of blood cells reliably determine the na-  
ture of metabolic disorders with DM 1 in children and

affect the course of CT. Violation of the activity of the  
enzymes of energy supply and hydrolysis in neutrophils  
and lymphocytes in patients indicates a decrease in the  
functional activity of these cell elements, which may af-  
fect their bactericidal and immunological protection in  
patients with DM 1 and CT, and also contribute to a  
more severe course of CT and frequent exacerbations  
of chronic diseases of lymphoepithelial pharyngeal for-  
mations

**Keywords:** diabetes mellitus 1 type, chronic tonsillitis,  
cytochemical analysis, acid phosphatase, succinate dehy-  
drogenase

## References

1. Barycheva, L. Y., Erdny-Goryaeva, N. E. (2013). Funktsional activity of neutrophils with type 1 diabetes in children. FUNDAMENTAL RESEARCH, 9, 32.
2. Biryukov, A. V., Gurov, A. V., Yushkina, M. O. (2012). Diabetes and purulent-inflammatory diseases of ENT-organs. Diabetes, 2, 54–59.
3. Vdovichenko, N. I., Tupotilov, A. V., Boiko, A. A., Carol, A. (2015). Features violations of humoral immunity in patients with chronic tonsillitis in the presence of diabetes and their correction. Annals of Mechnikov Institute, 2, 215–219.
4. Shishkov, V. N. (2015). Features of acute and chronic inflammation of the upper respiratory tract in patients with diabetes. Consilium Medicum, 17 (4), 40–43.
5. Alves, C., Casqueiro, J., Casqueiro, J. (2012). Infections in patients with diabetes mellitus: A review of pathogenesis. Indian Journal of Endocrinology and Metabolism, 16 (7), 27. doi: 10.4103/2230-8210.94253
6. Gordin, D., Forsblom, C., Rönneback, M., Parkkonen, M., Wadén, J., Hietala, K., Groop, P.-H. (2008). Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Annals of Medicine, 40 (8), 627–633. doi: 10.1080/07853890802126547
7. Lo, H.-C., Lin, S.-C., Wang, Y.-M. (2004). The relationship among serum cytokines, chemokine, nitric oxide, and leptin in children with type 1 diabetes mellitus. Clinical Biochemistry, 37 (8), 666–672. doi: 10.1016/j.clinbiochem.2004.02.002
8. Kuczyński, S., Winiarska, H., Abramczyk, M., Szczawińska, K., Wierusz-Wysocka, B., Dworacka, M. (2005). IL-15 is elevated in serum patients with type 1 diabetes mellitus. Diabetes Research and Clinical Practice, 69 (3), 231–236. doi: 10.1016/j.diabres.2005.02.007
9. Muller, L. M. A. J., Gorter, K. J., Hak, E., Goudzwaard, W. L., Schellevis, F. G., Hoepelman, A. I. M., Rutten, G. E. H. M. (2005). Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus. Clinical Infectious Diseases, 41 (3), 281–288. doi: 10.1086/431587
10. Shah, B. R., Hux, J. E. (2003). Quantifying the Risk of Infectious Diseases for People With Diabe-

tes. *Diabetes Care*, 26 (2), 510–513. doi: 10.2337/di-acare.26.2.510

11. Simonsen, J. R., Harjutsalo, V., Järvinen, A., Kirveskari, J., Forsblom, C., Groop, P.-H., Lehto, M. (2015). Bacterial infections in patients with type 1 diabetes: a 14-year follow-up study. *BMJ Open Diabetes Research & Care*, 3 (1), e000067. doi: 10.1136/bmjdr-2014-000067

12. Cytochemical diagnostics in laboratory hematology: Methodological guidance. Atlas (2008). Sankt-Peterburg, 80.

13. Berston, M. (1965). *Histochemiya fermentov*. Moscow: MIR, 464.

14. Karlow, L. S. (1955). Histochemical Procedure for Localizing and Evaluating Leucocyte Alkaline Phosphatase Activity in Smears of Blood and Marrow. *Blood*, 10 (10), 1023–1029.

15. Takeshima, Y., Iwasaki, Y., Okamura, T., Fujio, K., Yamamoto, K. (2017). The metabolic regulation in immune cells and pathogenesis of systemic lupus erythematosus ~toward new therapeutic applications~. *Japanese Journal of Clinical Immunology*, 40 (1), 12–20. doi: 10.2177/jsci.40.12

16. Nakajima, A., Nakatani, A., Hasegawa, S., Irie, J., Ozawa, K., Tsujimoto, G. et. al. (2017). The short chain fatty acid receptor GPR43 regulates inflammatory signals in adipose tissue M2-type macrophages. *PLOS ONE*, 12 (7), e0179696. doi: 10.1371/journal.pone.0179696

DOI: 10.15587/2519-4798.2018.127004

## PURINS DYSMETABOLISM IN PATIENT WITH GOUT AND ITS ASSOCIATION WITH DYSADIPOKINEMIA

p. 18-22

**Inna Orlova**, Postgraduate Student, Department of Internal Medicine No. 1, National Pirogov Memorial Medical University, Pyrohova str., 56, Vinnytsya, Ukraine, 21018  
E-mail: orlovainna17@gmail.com

ORCID: <http://orcid.org/0000-0001-7490-6794>

**Mykola Stanislavchuk**, MD, Professor, Head of Department, Department of Internal Medicine No. 1, National Pirogov Memorial Medical University, Pyrohova str., 56, Vinnytsya, Ukraine, 21018

E-mail: mstanislav53@yahoo.com

ORCID: <http://orcid.org/0000-0001-8160-8189>

**Aim of the research** was the study of the features of the exchange of urea acid in patients with gout and assessment of their connection with disadypokinemia.

**Materials and methods.** In the study took part 151 patients with gout and 31 person from control group. The level of uric acid in the serum of blood and urine was de-

termined by the biochemical method, the level of leptin and adyponectin by the enzyme-linked immunosorbent assay. The evaluation of the correlation between uric acid metabolism and disadypokinemia was performed using the Pearson correlation coefficient. Student's t-criterion was used to assess the differences between the groups.

**Results.** It turned out that in patients with gout there is a significant increase in the level of UA in the blood, lower clearance of UA and low fractional excretion compared with the control group. Disadypokinemia was also more pronounced in the group of patients with gout. In subjects with severe disadypokinemia, higher values of hyperuricemia were observed, a significantly lower excretion of UA with urine, reduced clearance and fractional excretion of UA.

**Conclusions.** Patients with gout have a rise in uricemia with reduced clearance and fractional excretion of UA. An associative connection between adypokin status in patients with gout and urinary acid metabolism was established

**Keywords:** gout, leptin, adyponectin, adyponectin / leptin ratio, uric acid metabolism

## References

1. Kuo, C.-F., Grainge, M. J., Mallen, C., Zhang, W., Doherty, M. (2014). Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. *Annals of the Rheumatic Diseases*, 74 (4), 661–667. doi: 10.1136/annrheumdis-2013-204463

2. Trifiro, G., Morabito, P., Cavagna, L., Ferrajolo, C., Pecchioli, S., Simonetti, M. et. al. (2011). Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. *Annals of the Rheumatic Diseases*, 72 (5), 694–700. doi: 10.1136/annrheumdis-2011-201254

3. Zhu, Y., Pandya, B. J., Choi, H. K. (2011). Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. *Arthritis & Rheumatism*, 63 (10), 3136–3141. doi: 10.1002/art.30520

4. Ayina, C. N. A., Endomba, F. T. A., Mandengue, S. H., Noubiap, J. J. N., Ngoa, L. S. E., Boudou, P. et. al. (2017). Association of the leptin-to-adiponectin ratio with metabolic syndrome in a sub-Saharan African population. *Diabetology & Metabolic Syndrome*, 9 (1). doi: 10.1186/s13098-017-0265-6

5. Bedir, A., Topbas, M., Tanyeri, F., Alvur, M., Arik, N. (2003). Leptin Might be a Regulator of Serum Uric Acid Concentrations in Humans. *Japanese Heart Journal*, 44 (4), 527–536. doi: 10.1536/jhj.44.527

6. Neogi, T., Jansen, T. L. T. A., Dalbeth, N., Fransen, J., Schumacher, H. R., Berendsen, D. et. al. (2015). 2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheuma-

tism Collaborative Initiative. *Arthritis & Rheumatology*, 67 (10), 2557–2568. doi: 10.1002/art.39254

7. Verhave, J. C., Balje-Volkers, C. P., Hillege, H. L., De Zeeuw, D., De Jong, P. E. (2003). The reliability of different formulae to predict creatinine clearance. *Journal of Internal Medicine*, 253 (5), 563–573. doi: 10.1046/j.1365-2796.2003.01141.x

8. Gillen, M., Valdez, S., Zhou, D., Kerr, B., Lee, C. A., Shen, Z. (2016). Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. *Drug Design, Development and Therapy*, 10, 3555–3562. doi: 10.2147/dddt.s119944

9. Liu, S., Perez-Ruiz, F., Miner, J. N. (2017). Patients with gout differ from healthy subjects in renal response to changes in serum uric acid. *Joint Bone Spine*, 84 (2), 183–188. doi: 10.1016/j.jbspin.2016.04.007

10. Kotani, K., Sakane, N. (2011). Leptin:Adiponec-tin Ratio and Metabolic Syndrome in the General Japanese Population. *The Korean Journal of Laboratory Medicine*, 31 (3), 162–166. doi: 10.3343/kjlm.2011.31.3.162

11. Samara, A., Herbeth, B., Aubert, R., Berrah-moune, H., Fumeron, F., Siest, G., Visvikis-Siest, S. (2010). Sex-dependent Associations of Leptin With Metabolic Syndrome-related Variables: The Stanislas Study. *Obesity*, 18 (1), 196–201. doi: 10.1038/oby.2009.156

DOI: 10.15587/2519-4798.2018.127559

**THE INFLUENCE OF RISK FACTORS IN PATIENTS WITH ULCER DISEASE ON THE DURATION AND MULTIPLICITY OF THE TREATMENT IN RESIDENTS OF VINNYTSIA REGION**

p. 23-26

**Nataliia Kizlova**, PhD, assistant, Department of Social Medicine and Organization of public health services, M. I. Pirogov National Medical University, Pirogova str., 56, Vinnytsya, Ukraine, 21018

E-mail: gastrovokl@gmail.com

ORCID: <http://orcid.org/0000-0003-3228-766X>

**Olena Komar**, MD, Professor, Department of Social Medicine and Organization of public health services, M. I. Pirogov National Medical University, Pirogova str., 56, Vinnytsya, Ukraine, 21018

E-mail: olenakrekoten77@gmail.com

ORCID: <http://orcid.org/0000-0001-9407-5350>

**Oleksandra Trylevych**, Intern, M. I. Pirogov National Medical University, Pirogova str., 56, Vinnytsya, Ukraine, 21018

E-mail: floydcoct@gmail.com

ORCID: <http://orcid.org/0000-0003-1186-2733>

*The aim of the study is to reveal the influence of the risk factors in patients with gastric and duodenal peptic ulcer on duration and multiplicity of the treatment in residents of Vinnytsia region.*

*Methods.* As the materials for research we used reporting forms from Vinnitsia state medical institutions: inpatient cards 003/0, outpatient cards 025/0 (total n=700 with duodenal and gastric ulcer), cards of patients who left the hospital, questionnaires. In order to calculate the dependence between the risk factors and duration and multiplicity of treatment thereof we used the criteria of score valuation of the Charlson index, which accumulates the comorbidity of diseases.

*Result.* The results of quantitative evaluation of the factors scoring suggest of the underlying *H.pylori* infection (the significance of which is growing along with the growth of the disease incidence) and comorbidity as the most important ones. There is a linear dependence between the risk factors and the necessity for specialized care, which was manifested in the duration and multiplicity of treatment.

*Conclusions.* We have established the direct dependence between the most important peptic ulcer risk factors, severity of the disease, and duration and periodicity of treatment thereof during the year in the day gastroenterological hospital. We revealed the necessity for formation of risk groups among the population, each of which requires a systematic approach to studying the general condition, taking into account existing illnesses, their negative interactions. The best method of improving the medical care organization is active-constructive prophylaxis

**Keywords:** gastric ulcer and duodenal ulcer; risk factors, duration and multiplicity of treatment

**References**

1. Koh, H. K. (2010). A 2020 Vision for Healthy People. *New England Journal of Medicine*, 362 (18), 1653–1656. doi: 10.1177/1090198111428646

2. Walker, A. E. (2007). Many chronic diseases and quality of life: Models that come from a large national sample. *Australia*, 31.

3. Shafranskii, V. V. (Ed.) (2016). Annual report on the health status of the population, the sanitary and epidemiological situation and the results of the health care system of Ukraine. 2015 year. Kyiv, 452.

4. Lukicheva, T. A., Fokin, M. V. (2012). Investigation of the state of health of the population in the methodology of risk assessment. *Hygiene and sanitation*, 5, 103–105.

5. Mytnyk, Z. M. (Ed.) (2010). Health of the population and activity of the Ukrainian health care system: realities, problems and solutions. Kyiv, 107.

6. Dzvonkovska, T. T., Neiko, V. E. (2007). A Differential Approach to the Treatment of Patients with Acid-Dependent Diseases Associated With Various *Helicobacter Pylori* Strains. *Archive of clinical medicine*, 2, 73–74.

7. Moskalenko, V. F. (2013). Risk factors for health are an important and effective resource on the way of improving the health of the population, increasing the life expectancy of people. *Medical perspectives*, 2, 102–108.

8. Annual report on the health status of the population, the sanitary and epidemiological situation and the results of the health care system of Ukraine. 2016 year (2017). Kyiv, 516.

9. State Statistics Committee of Ukraine Statistical Yearbook of Ukraine, 2016 (2016). Kyiv.

10. Lazorishin, V. V. et. al. (2014). Health care in Ukraine: state, problems, perspectives. Kyiv, 608.

11. Tutchenko, M. I., Yaroshchuk, D. V., Vasilchuk, O. V., Markulan, L. Y. (2014). Risk Factors for Relapse of Pulmonary Disease after Palliative Open and Laparoscopic Interventions Concerning Perforated Duodenal ulcer. *Khirurgiya Ukrainy*, 1, 15–22.

12. Rosenstock, S. (2003). Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. *Gut*, 52 (2), 186–193. / doi: 10.1136/gut.52.2.186

-----  
DOI: 10.15587/2519-4798.2018.127276

#### GALECTIN-3 SERUM PROFILE IN PATIENTS WITH KNEE OSTEOARTHRITIS: ASSOCIATION WITH THE DISEASE COURSE

p. 27-32

**Oksana Humeniuk**, Researcher, Scientific Research Institute of Rehabilitation of National Pirogov Memorial Medical University, Khmelnytske shose str., 104, Vinnytsia, Ukraine, 21029, Department of Internal Medicine No.1, National Pirogov Memorial Medical University, Pyrohova str., 56, Vinnytsia, Ukraine, 21018  
E-mail: oxana.gumenuk@gmail.com

**Mykola Stanislavchuk**, MD, Professor, Head of Department, Department of Internal Medicine No. 1, National Pirogov Memorial Medical University, Pyrohova str., 56, Vinnytsia, Ukraine, 21018  
E-mail: stanislav53@yahoo.com  
ORCID: <http://orcid.org/0000-0001-8505-5999>

**Natalia Zaichko**, MD, Professor, Head of Department, Department of Biological and General Chemistry, National Pirogov Memorial Medical University, Pyrohova str., 56, Vinnytsia, Ukraine, 21018  
E-mail: nzaichko@vnm.edu.ua  
ORCID: <http://orcid.org/0000-0003-1889-6151>

*Aim of the work* was to study the level of galectin-3 in serum in patients with osteoarthritis of knee joints and to evaluate its association with the course of the disease.

**Materials and methods.** We examined 141 patients with osteoarthritis (OA) of knee joints (76.6 % of women), an average age of 58.4±7.91 years, a disease duration of 10.5±6.50 years, an II–III radiological stage. 33.3 % of patients had a combination of OA knee and hip joints. Diagnosis of OA was established on the basis of criteria ACR 1991 and recommendations EULAR (2010). The Lequesne algo-functional index, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS) were determined. Functional disorders were evaluated by the Health Assessment Questionnaire (HAQ). The content of galectin-3 in the blood was determined by the enzyme-linked immuno sorbent assay.

**Results.** It has been established that in 75 % of patients with OA of knee joints aberrant levels of galectin-3 in the blood are detected, including 44 % of subjects with a registered high level of the index (>15.8 ng/ml). The weak associative relationships between the level of galectin-3 and the age of patients and the duration of OA were established. Among patients with aberrant levels of galectin-3, persons with severe clinical manifestations of OA appeared more often. The increase in the level of galectin-3 was associated with a significant increase in the pain syndrome and the deterioration of physical function by the indexes of Lequesne, WOMAC, KOOS, HAQ.

**Conclusions.** In patients with OA, the increase in the production of galectin-3 is a factor in the deterioration of the clinical course of the disease, the increase in pain syndrome and functional disorders. A close associative relationship was found between the level of galectin-3 and the clinical severity indexes of OA and the weak associative relationship between the level of galectin-3 and the age and duration of the disease

**Keywords:** galectin-3, osteoarthritis, knee joint, gonarthrosis, Lequesne index, WOMAC, KOOS, HAQ

#### References

1. Kovalenko, V. M., Bortkevych, O. P. (2011) Osteoartroz i bil: stan problemy [Osteoarthritis and pain: the condition of the problem]. *Bol. Sustavy. Pozvonochnyk* [Pain. Joints. Spine], 1 (1). Available at: <http://www.mif-ua.com/archive/article/16189>
2. Stasenko, T. (2017) Osteoartroz: optimalnyi vybir dlya uspishnogo likuvannya [Osteoarthritis: the best choice for successful treatment]. *Ukrayinskyi medychnyi chasopys* [Ukrainian medical journal], 2 (118). Available at: <https://www.umj.com.ua/article/107694/osteoartroz-optimalnij-vibir-dlya-uspishnogo-likuvannya>
3. Bruyere, O., Cooper, C., Pelletier, J.-P., Maheu, E., Rannou, F., Branco, J. et. al. (2016). A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis—From evidence-based medicine to the real-life setting. *Seminars*

in Arthritis and Rheumatism, 45 (4), 3–11. doi: 10.1016/j.semarthrit.2015.11.010

4. Johnson, V., Giuffre, B., Hunter, D. (2012). Osteoarthritis: What Does Imaging Tell Us about Its Etiology? *Seminars in Musculoskeletal Radiology*, 16 (5), 410–418. doi: 10.1055/s-0032-1329894

5. Toegel, S., Bieder, D., Andre, S., Kayser, K., Walzer, S. M., Hobusch, G. et. al. (2014). Human osteoarthritic knee cartilage: fingerprinting of adhesion/growth-regulatory galectins in vitro and in situ indicates differential upregulation in severe degeneration. *Histochemistry and Cell Biology*, 142 (4), 373–388. doi: 10.1007/s00418-014-1234-x

6. Weinmann, D., Schlangen, K., Andre, S., Schmidt, S., Walzer, S. M., Kubista, B. et. al. (2016). Galectin-3 Induces a Pro-degradative/inflammatory Gene Signature in Human Chondrocytes, Teaming Up with Galectin-1 in Osteoarthritis Pathogenesis. *Scientific Reports*, 6 (1). doi: 10.1038/srep39112

7. Toegel, S., Bieder, D., Andre, S., Altmann, F., Walzer, S. M., Kaltner, H. et. al. (2013). Glycophenotyping of osteoarthritic cartilage and chondrocytes by RT-qPCR, mass spectrometry, histochemistry with plant/human lectins and lectin localization with a glycoprotein. *Arthritis Research & Therapy*, 15 (5), 147. doi: 10.1186/ar4330

8. Janelle-Montcalm, A., Boileau, C., Poirier, F., Pelletier, J.-P., Guevremont, M., Duval, N. et. al. (2007). Extracellular localization of galectin-3 has a deleterious role in joint tissues. *Arthritis Research & Therapy*, 9 (1), 20. doi: 10.1186/ar2130

9. Boileau, C., Poirier, F., Pelletier, J.-P., Guevremont, M., Duval, N., Martel-Pelletier, J., Reboul, P. (2007). Intracellular localisation of galectin-3 has a protective role in chondrocyte survival. *Annals of the Rheumatic Diseases*, 67 (2), 175–181. doi: 10.1136/ard.2006.066514

10. Ezzat, M. H. M., El-Gammasy, T. M. A., Shaheen, K. Y. A., Osman, A. O. Y. (2011). Elevated production of galectin-3 is correlated with juvenile idiopathic arthritis disease activity, severity, and progression. *International Journal of Rheumatic Diseases*, 14 (4), 345–352. doi: 10.1111/j.1756-185x.2011.01632.x

11. Issa, S. F., Duer, A., Ostergaard, M., Horslev-Petersen, K., Hetland, M. L., Hansen, M. S. et. al. (2017). Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets. *Arthritis Research & Therapy*, 19 (1), 80. doi: 10.1186/s13075-017-1282-4

12. Altman, R. D. (1991). Criteria for the classification of clinical osteoarthritis. *The Journal of Rheumatology*, 18, 10–12.

13. Zhang, W., Doherty, M., Peat, G., Bierma-Zeinstra, M. A., Arden, N. K., Bresnihan, B. et. al. (2010). EULAR evidence-based recommendations for the diagnosis

of knee osteoarthritis. *Annals of the Rheumatic Diseases*, 69 (3), 483–489. doi: 10.1136/ard.2009.113100

14. Lequesne, M. G. (1997). The algofunctional indices for hip and knee osteoarthritis. *The Journal of Rheumatology*, 24 (4), 779–781.

15. Bellamy, N., Buchanan, W., Goldsmith, C. et. al. (1988). Validation study of WOMAC: A Health Status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *The Journal of Rheumatology*, 15 (12), 1833–1840.

16. Roos, E. M., Roos, H. P., Lohmander, L. S., Ekdahl, C., Beynon, B. D. (1998). Knee Injury and Osteoarthritis Outcome Score (KOOS)—Development of a Self-Administered Outcome Measure. *Journal of Orthopaedic & Sports Physical Therapy*, 28 (2), 88–96. doi: 10.2519/jospt.1998.28.2.88

17. Bruce, B., Fries, J. F. (2003). The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. *Health and Quality of Life Outcomes*, 1 (1), 20. doi: 10.1186/1477-7525-1-20

18. De Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L. et. al. (2012). The fibrosis marker galectin-3 and outcome in the general population. *Journal of Internal Medicine*, 272 (1), 55–64. doi: 10.1111/j.1365-2796.2011.02476.x

19. Krintus, M., Kozinski, M., Fabiszak, T., Kubicka, J., Panteghini, M., Sypniewska, G. (2017). Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. *Clinical Biochemistry*, 50 (10-11), 599–604. doi: 10.1016/j.clinbiochem.2017.03.015

-----  
**DOI: 10.15587/2519-4798.2018.127681**

## **RESULTS OF TREATMENT AND CRITERIA OF PROGRESS OF RESPIRATORY ORGANS SARKOIDOSIS**

**p. 33-38**

**Kostiantyn Shvets**, Assistant, Department of Pulmonology and Phthisiology with a course of Occupational Diseases, SHEE “Ivano-Frankivsk National Medical University”, Galitska str., 2, Ivano-Frankivsk, Ukraine, 76000

**E-mail:** meduk1303@gmail.com

**ORCID:** <http://orcid.org/0000-0001-8025-6054>

**Mykola Ostrovskyy**, MD, Professor, Head of Department, Department of Pulmonology and Phthisiology with a course of Occupational Diseases, SHEE “Ivano-Frankivsk National Medical University”, Galitska str., 2, Ivano-Frankivsk, Ukraine, 76000

**E-mail:** dr.ostrovskyyi@rambler.ru

**ORCID:** <http://orcid.org/0000-0002-3922-0583>

**The aim of the work.** This research work is devoted to the development of new additional criteria for the activity of inflammatory process in sarcoidosis of respiratory organs. The goal is to assess the effectiveness of performed treatment of sarcoidosis of respiratory organs by using low-cost highly-sensitive inflammatory markers.

**Materials and methods.** The study involved 68 patients with lung sarcoidosis before and after the three-month treatment. In addition to general-clinical methods of examination, in patients with sarcoidosis we also determined the levels of TNF- $\alpha$  and IL-2.

**Results.** Patients with active lung sarcoidosis had 2.61 times ( $p < 0.05$ ) increased level of IL-2 in bronchoalveolar lavage fluid and 9.05 times ( $p < 0.05$ ) increased levels in peripheral blood serum; the levels of TNF- $\alpha$  increased by 4.98 times ( $p < 0.05$ ) in bronchoalveolar lavage fluid and by 3.2 times ( $p < 0.05$ ) in peripheral blood serum as compared to the findings in the control group of patients. The study showed that in the group of patients, where the efficacy of the prescribed therapy was noted, the level of IL-2 decreased by 2.08 times ( $p < 0.05$ ) in bronchoalveolar lavage fluid and by 3.76 times ( $p < 0.05$ ) in peripheral blood serum, and the concentration of TNF- $\alpha$  decreased by 3.87 times ( $p < 0.05$ ) in bronchoalveolar lavage fluid and by 2.06 times in peripheral blood serum as compared to the initial indices.

**Conclusions.** The decrease of TNF- $\alpha$  level in bronchoalveolar lavage fluid on the background of three-months treatment correlated ( $r = 0.84$ ;  $p < 0.05$ ) to the changes in peripheral blood serum; at the same time the decrease of TNF- $\alpha$  level in peripheral blood serum correlated ( $r = 0.89$ ;  $p < 0.05$ ) to the decrease of IL-2 in peripheral blood serum of patients with sarcoidosis of respiratory organs

**Keywords:** sarcoidosis of respiratory organs, activity criteria, treatment, prognosis, interleukin-2

## References

1. Feshchenko, Y. I., Protsyk, L. M., Cherednyk, Y. O. (2006). Sarkoidoz orhaniv dykhannia: suchasnyi stan problemy [Sarcoidosis of respiratory organs: present state of the problem]. *Ukrainskyi pulmonologichnyi zhurnal*, 3, 5–10.
2. Gavrysyuk, V. K. (2010). Sarkoidoz organov dihaniya [Pulmonary Sarcoidosis]. *Zdorovia Ukrainy*, 2, 29–31.
3. Gribbin, J., Hubbard, R. B., Le Jeune, I., Smith, C. J. P., West, J., Tata, L. J. (2006). Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. *Thorax*, 61 (11), 980–985. doi: 10.1136/thx.2006.062836
4. Karakatsani, A., Papakosta, D., Rapti, A., Antoniou, K. M., Dimadi, M., Markopoulou, A. et al. (2009). Epidemiology of interstitial lung diseases in Greece. *Respiratory Medicine*, 103 (8), 1122–1129. doi: 10.1016/j.rmed.2009.03.001
5. Ahmadzai, H., Loke, W. S. J., Huang, S., Herbert, C., Wakefield, D., Thomas, P. (2014). Biomarkers in sarcoidosis: a review. *Current Biomarker Findings*, 93. doi: 10.2147/cbf.s46196
6. Hunninghake, G. W., Costabel, U., Ando, M., Baughman, R., Cordier, J. F., du Bois, R. et al. (1999). ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. *Sarcoidosis Vasc Diffuse Lung Dis*, 16 (2), 149–173.
7. Havrysiuk, V. K., Merenkova, Ye. O., Humeniuk, H. L., Shadrina, O. V. (2014). Sarkoidoz organov dihaniya: epidemiologiya, klinicheskie formy i stadiyi, rezul'taty lecheniya [Pulmonary sarcoidosis: epidemiology clinical forms and stages, results of treatment]. *Zdorovia Ukrainy*, 1 (25), 32–33.
8. Baughman, R. P., Nunes, H., Sweiss, N. J., Lower, E. E. (2013). Established and experimental medical therapy of pulmonary sarcoidosis. *European Respiratory Journal*, 41 (6), 1424–1438. doi: 10.1183/09031936.00060612
9. Mannino, D. M., Ford, E. S., & Redd, S. C. (2003). Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination. *The American Journal of Medicine*, 114 (9), 758–762. doi: 10.1016/s0002-9343(03)00185-2
10. Sweiss, N. J., Curran, J., Baughman, R. P. (2007). Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. *Clinics in Dermatology*, 25 (3), 341–346. doi: 10.1016/j.clindermatol.2007.03.012
11. Meyer, K. C., Raghu, G. (2011). Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? *European Respiratory Journal*, 38 (4), 761–769. doi: 10.1183/09031936.00069509
12. Takahashi, T., Azuma, A., Abe, S., Kawanami, O., Ohara, K., Kudoh, S. (2001). Significance of lymphocytosis in bronchoalveolar lavage in suspected ocular sarcoidosis. *European Respiratory Journal*, 18 (3), 515–521. doi: 10.1183/09031936.01.99104501
13. Baughman, R. P., Culver, D. A., Judson, M. A. (2011). A Concise Review of Pulmonary Sarcoidosis. *American Journal of Respiratory and Critical Care Medicine*, 183 (5), 573–581. doi: 10.1164/rccm.201006-0865Sci
14. Pepys, M. B., Hirschfield, G. M. (2003). C-reactive protein: a critical update. *Journal of Clinical Investigation*, 111 (12), 1805–1812. doi: 10.1172/jci18921
15. Costabel, U. (2001). Sarcoidosis: clinical update. *European Respiratory Journal*, 18, 56s–68s.
16. Sahoo, D. H., Bandyopadhyay, D., Xu, M., Pearson, K., Parambil, J. G., Lazar, C. A. et al. (2011). Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. *European Respiratory Journal*, 38 (5), 1145–1150. doi: 10.1183/09031936.00195010

DOI: 10.15587/2519-4798.2018.128014

## CLINICAL CHARACTERISTICS OF SCHOOL-AGED CHILDREN WITH ESOPHAGUS DISEASES

p. 39-43

**Olga Belousova**, MD, Professor, Head of the Department, Department of Pediatric Gastroenterology and Nutrition, Kharkiv Medical Academy of Postgraduate Education, Amosova str., 58, Kharkiv, Ukraine, 61176

E-mail: olga.yu.belousova@gmail.com

ORCID: <http://orcid.org/0000-0003-4983-1713>

**Oleksandra Slobodianiuk**, Postgraduate student, Department of Pediatric Gastroenterology and Nutrition, Kharkiv Medical Academy of Postgraduate Education, Amosova str., 58, Kharkiv, Ukraine, 61176

E-mail: oleksandra.slobodianiuk@gmail.com

ORCID: <http://orcid.org/0000-0002-6400-4735>

**Nataliia Pavlenko**, PhD, Associate professor, Department of pediatric gastroenterology and nutrition, Kharkiv Medical Academy of Postgraduate Education, Amosova str., 58, Kharkiv, Ukraine, 61176

E-mail: pavlenko.nat.v@gmail.com

ORCID: <http://orcid.org/0000-0002-8882-755X>

*In pediatric, because of diversity of clinical symptoms and difficulties of invasive surveying methods, there is a constant search of methods of early diagnosis, optimal treatment and course prediction. Clinical symptoms, risk factors, peculiarities of GERD coursing for school-aged children are examined in the article.*

**Methods.** It is included 93 patients (6–18 years) with clinical symptoms, typical for gastroduodenal pathologies. Children surveying involved detailed medical histories gathering, specification of feeding patterns, feeding regularity, daily regime, presence of chronic stress, sleep duration, presence of bad habits and bad feeding habits. From history of life – duration of breast-feeding and start of eating first food. Common clinical analyses: biochemical blood analysis, lipid profile, upper endoscopy with intragastral endoscopic pH-meter were applied.

**Results.** Based on endoscopic surveying, three sub-groups were obtained: GERD-positive children without esophagitis, GERD-positive with esophagitis (catarrhal esophagitis), and GERD-positive with esophagitis (erosive esophagitis). Depending on GERD form, in both groups presence of risk factors was evaluated. Both groups were interviewed with questionnaire by Vein (2003). Symptoms of autonomic dysfunction was detected for 88.04 % of patients (more than 15 points by questionnaire).

**Conclusions.** Conducted research showed diversion of GERD main clinical symptoms for children of two age groups: 6–11 and 12–18 y.o, and also relationship between separate risk factors and different forms of GERD. Opti-

mization of primary screening diagnosis can be achieved by applying GERDQ-type kid's questionnaire

**Keywords:** gastroesophageal reflux disease, children, diagnosis, questionnaire, esophageal symptoms, extra-esophageal symptoms

## References

1. World Gastroenterology Organisation Global Guidelines: GERD. Global Perspective on Gastroesophageal Reflux Disease (2015). Available at: <http://www.worldgastroenterology.org/guidelines/global-guidelines/gastroesophageal-reflux-disease/gastroesophageal-reflux-disease-english>
2. Zubarenko, O. V., Kravchenko, T. Yu. (2013). Suchasnyi pohliad na hastroezofahealnu refliuksnu khvorobu u ditei [The modern view of gastroesophageal reflux disease in children]. *Perynatolohiia i pediatriia*, 1, 114–122.
3. Nyankovskyy, S. L., Horodylovska, M. I., Ivantsiv, V. A., Boyko, O. I. (2017). Differentiated Diagnosis of Esophagitis in Schoolchildren. *Child'S Health*, 8 (76), 56–61. doi: 10.22141/2224-0551.8.76.2016.90825
4. Mohammed, I., Cherkas, L. F., Riley, S. A., Spector, T. D., Trudgill, N. J. (2003). Genetic influences in gastro-oesophageal reflux disease: a twin study. *Gut*, 52 (8), 1085–1089. doi: 10.1136/gut.52.8.1085
5. Fadeenko, H. D., Kushnyr, Y. E., Babak, M. O. (2008). Epydemyolohycheskye aspekty hastroezofahealnoi refliuksnoi bolezny [Epidemiological aspects of gastroesophageal reflux disease. *Suchasna hastroenteroliia*, 5 (43), 12–16.
6. Jung, H.-K. (2011). Epidemiology of Gastroesophageal Reflux Disease in Asia: A Systematic Review. *Journal of Neurogastroenterology and Motility*, 17 (1), 14–27. doi: 10.5056/jnm.2011.17.1.14
7. Palii, I. H., Zaika, S. V., Yankovetska, A. H. (2015). Poshyrennia hastroezofahealnoi refliuksnoi khvoroby sered khvorykh z patolohiieiu orhaniv travleniia, provokuiuchi chynnyky ta efektyvnist blokatoriv N+/K+ATFazy (za rezultatamy anketuvannia ambulatornykh khvorykh) [Distribution of gastroesophageal reflux disease among patients with pathology of the digestive system, provocative factors and the effectiveness of N+/K+ATPase blockers (according to the results of the survey of ambulatory patients)]. *Suchasna hastroenterolohiia*, 2, 85–96.
8. Shadrin, O. H., Ihnatko, L. V. (2016). Suchasni pidkhody do diahnozyky ta likuvannia hastroezofahealnoi refliuksnoi khvoroby u ditei [Modern approaches to the diagnosis and treatment of gastroesophageal reflux disease in children]. *Zdorovia Ukrainy. Spets. vypusk «Hastroenterolohiia, hematolohiia, koloproktolohiia»*, 3 (41). Available at: <http://health-ua.com/article/4328-suchasn-pd-hodi-dodagnostiki-talkuvannya-gastroezofagealno-reflyuk-sno-hvorob>

9. Zubarenko, O. V., Kravchenko, T. Yu., Loseva, K. O. (2012). Hastroezofahealnaia refliuksnaia bolezn u detei: sovremennyi vzglihat na patohenez i kliniku [Gastroesophageal reflux disease in children: modern view of pathogenesis and clinic]. *Zdorov'e rebenka*, (1 (36)), 112–117.
10. Rosen, R., Vandenplas, Y., Singendonk, M., Cabana, M., DiLorenzo, C., Gottrand, F. et. al. (2018). Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. *Journal of Pediatric Gastroenterology and Nutrition*, 66 (3), 516–554. doi: 10.1097/mpg.0000000000001889
11. Pediatric Gastroesophageal Reflux Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability (2017). *Federal Register*, 82 (207), 49837–49838. Available at: <https://www.federalregister.gov/d/2017-23436/p-3>
12. Davies, I., Burman-Roy, S., Murphy, M. S. (2015). Guideline Development Group. Gastro-oesophageal reflux disease in children: NICE guidance. *BMJ*, 350, 7703–7703. doi: 10.1136/bmj.g7703
13. Martigne, L., Delaage, P.-H., Thomas-Delcourt, F., Bonnelye, G., Barthélémy, P., Gottrand, F. (2012). Prevalence and management of gastroesophageal reflux disease in children and adolescents: a nationwide cross-sectional observational study. *European Journal of Pediatrics*, 171 (12), 1767–1773. doi: 10.1007/s00431-012-1807-4
14. Farahmand, F., Sabbaghian, M., Ghodousi, S., Seddighorae, N., Abbasi, M. (2013). Gastroesophageal Reflux Disease and Tooth Erosion: A Cross-Sectional Observational Study. *Gut and Liver*, 7 (3), 278–281. doi: 10.5009/gnl.2013.7.3.278
15. Ness-Jensen, E., Hveem, K., El-Serag, H., Lagergren, J. (2016). Lifestyle Intervention in Gastroesophageal Reflux Disease. *Clinical Gastroenterology and Hepatology*, 14 (2), 175–182. doi: 10.1016/j.cgh.2015.04.176